Integrin α2β1 regulates neutrophil recruitment and inflammatory activity in experimental colitis in mice

Inflammatory Bowel Diseases

Volumn 12, Issue 3, 2006, Pages 172-177

  Lundberg, Sofie ^a   Lindholm, Johan ^a   Lindbom, Lennart ^b   Hellström, Per M ^a   Werr, Joachim ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; BETA1 INTEGRIN; BETAMETHASONE; DEXTRAN SODIUM SULFATE; DRINKING WATER; METALLOPROTEINASE; MONOCLONAL ANTIBODY; SODIUM SULFATE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2;

ARTICLE; COLON MUCOSA; CONTROLLED STUDY; ENTERITIS; GENE EXPRESSION; HISTOLOGY; HUMAN; INFLAMMATORY DISEASE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; PROBABILITY; RANDOMIZATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BETAMETHASONE; BIOPSY, NEEDLE; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA2BETA1; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; PROBABILITY; RANDOM ALLOCATION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; WEIGHT LOSS;

EID: 33645106623     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000217765.96604.83     Document Type: Article

References (31)

1. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 1995;3:171-174.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
3. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998;114:1066-1090.
4. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
5. Lindbom L, Werr J. Integrin-dependent neutrophil migration in extravascular tissue. Semin Immunol. 2002;14:115-121.
6. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101.
7. Brakebusch C, Hirsch E, Potocnik A, et al. Genetic analysis of beta1 integrin function: confirmed, new and revised roles for a crucial family of cell adhesion molecules. J Cell Sci. 1997;110:2895-2904.
8. Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol. 1990;8:365-400.
9. Kubes P, Niu XF, Smith CW, et al. A novel beta 1-dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J. 1995;9:1103-1111.
10. Werr J, Xie X, Hedqvist P, et al. Beta1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. J Exp Med. 1998;187:2091-2096.
11. Ridger VC, Wagner BE, Wallace WA, et al. Differential effects of CD18, CD29, and CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. J Immunol. 2001;166:3484-3490.
12. Krieglstein CF, Cerwinka WH, Sprague AG, et al. Collagen-binding integrin alpha1 beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest. 2002;110:1773-1782.
13. Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther. 2000;295:183-189.
14. Soriano A, Salas A, Salas A, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000;80:1541-1551.
15. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
16. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
17. Werr J, Johansson J, Eriksson EE, et al. Integrin alpha(2)beta(1) (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. Blood. 2000;95:1804-1809.
18. Downey GP. Mechanisms of leukocyte motility and chemotaxis. Curr Opin Immunol. 1994;6:113-124.
19. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:291-300.
20. Farkas S, Hornung M, Sattler C, et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis. 2005;21:71-78.
21. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68-72.
22. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98:2232-2238.
23. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
24. Medina C, Videla S, Radomski A, et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G116-G122.
25. Naito Y, Takagi T, Kuroda M, et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res. 2004;53:462-468.
26. Wielockx B, Libert C, Wilson C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev. 2004;15:111-115.
27. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709.
28. Pirila E, Ramamurthy NS, Sorsa T, et al. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci. 2003;48:93-98.
29. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol. 2000;120:241-246.
30. Phillips JA, Bonassar LJ. Matrix metalloproteinase activity synergizes with alpha2beta1 integrins to enhance collagen remodeling. Exp Cell Res. 2005;310:79-87.
31. Mendrick DL, Kelly DM, duMont SS, et al. Glomerular epithelial and mesangial cells differentially modulate the binding specificities of VLA-1 and VLA-2. Lab Invest. 1995;72:367-375.